admune.com Home - Admune Therapeutics

admune.com
Title: Home - Admune Therapeutics
Keywords:
Description: Admune Therapeutics LLC is a clinical-stage biotech company focused on the development and delivery of cytokine therapy drugs for the treatment of various
admune.com is ranked 20311233 in the world (amongst the 40 million domains). A low-numbered rank means that this website gets lots of visitors. This site is relatively popular among users in the united states. It gets 50% of its traffic from the united states .This site is estimated to be worth $5,240. This site has a low Pagerank(0/10). It has 1 backlinks. admune.com has 43% seo score.

admune.com Information

Website / Domain: admune.com
Website IP Address: 64.207.139.199
Domain DNS Server: ns2.mediatemple.net,ns1.mediatemple.net

admune.com Rank

Alexa Rank: 20311233
Google Page Rank: 0/10 (Google Pagerank Has Been Closed)

admune.com Traffic & Earnings

Purchase/Sale Value: $5,240
Daily Revenue: $14
Monthly Revenue $430
Yearly Revenue: $5,240
Daily Unique Visitors 1,321
Monthly Unique Visitors: 39,630
Yearly Unique Visitors: 482,165

admune.com WebSite Httpheader

StatusCode 200
Cache-Control no-store, no-cache, must-revalidate, post-check=0, pre-check=0
Content-Type text/html; charset=utf-8
Date Tue, 16 Aug 2016 07:35:42 GMT
Server Apache/2.2.22

admune.com Keywords accounting

Keyword Count Percentage

admune.com Traffic Sources Chart

admune.com Similar Website

Domain Site Title

admune.com Alexa Rank History Chart

admune.com aleax

admune.com Html To Plain Text

Home - Admune Therapeutics 888.666.2560 Home About Technology Therapeutic Programs News Strategic Opportunities Developing Innovative, Effective Drug Therapies for Cancer Immunotherapy Admune Therapeutics LLC is a clinical-stage biotech company focused on the development and delivery of cytokine therapy drugs for the treatment of various cancers. Our goal is to provide effective pharmaceutical products that improve the quality of life for oncology patients with metastatic cancers including melanoma, renal cell carcinoma, non-small cell lung cancers (NSCLC) and others. Admune Therapeutics has received FDA authorization to move forward with a Phase I clinical study of our initial cytokine, hetIL-15. Enrollment for in-human studies has begun through the National Cancer Institute at the National Institutes of Health. About Technology Therapeutic Programs News Strategic Opportunities ? 2016 Admune Therapeutics. All rights reserved. Website by SFA Marketing

admune.com Whois

Whois Server Version 2.0
Domain names in the .com and .net domains can now be registered
with many different competing registrars. Go to http://www.internic.net
for detailed information.
  Domain Name: ADMUNE.COM
  Registrar: REGISTER.COM, INC.
  Sponsoring Registrar IANA ID: 9
  Whois Server: whois.register.com
  Referral URL: http://www.register.com
  Name Server: NS1.MEDIATEMPLE.NET
  Name Server: NS2.MEDIATEMPLE.NET
  Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
  Updated Date: 06-apr-2015
  Creation Date: 17-dec-2012
  Expiration Date: 17-dec-2019
>>> Last update of whois database: Mon, 16 May 2016 10:33:59 GMT <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars